Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine.

Özyörük, Derya; Yozgat, Ayça Koca; Kaçar, Dilek; Yazal Erdem, Arzu; Isik, Melek; Güzelküçük, Zeliha; Hacisalihoglu, Sadan

Özyörük, Derya; Yozgat, Ayça Koca; Kaçar, Dilek; Yazal Erdem, Arzu; Isik, Melek; Güzelküçük, Zeliha; Hacisalihoglu, Sadan.

Affiliation

Özyörük D; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Yozgat AK; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Kaçar D; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Yazal Erdem A; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Isik M; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Güzelküçük Z; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.
Hacisalihoglu S; Division of Pediatric Oncology, Ankara Children's Hematology and Oncology Education and Research Hospital, Ankara, Turkey.

Tumori ; 107(6): NP120-NP122, 2021 Dec.

Article de En | MEDLINE | ID: mdl-34423687

Sujet(s)
Mots clés

Langerhans cell histiocytosis; cyclosporine; relapsed-refractory

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Histiocytose à cellules de Langerhans / Ciclosporine / Immunosuppresseurs Type d'étude: Etiology_studies / Prognostic_studies Limites: Humans / Infant / Male Langue: En Journal: Tumori Année: 2021 Type de document: Article Pays d'affiliation: Turquie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google